Result of AGM

Renalytix PLC

15 December 2023

 

Renalytix plc

("Renalytix" or the "Company") 

Result of AGM

LONDON and SALT LAKE, 15 December 2023 - Renalytix (NASDAQ: RNLX) (LSE: RENX), an artificial intelligence-enabled in vitro diagnostics company, focused on optimizing clinical management of kidney disease to drive improved patient outcomes and advance value-based care, announces that at the Annual General Meeting ("AGM") held earlier today, all resolutions were duly passed.

The results of the AGM are detailed below:

	For	% voted in favour		Against	% voted against	Withheld
Ordinary resolutions
1 Accept Financial Statements and Statutory Reports	40,118,702	99.94%		24,743	0.06%	67,418
2 Approve Remuneration Report	39,959,034	99.44%		226,856	0.56%	24,973
3 Re-elect Cathy Coste	39,058,428	97.29%		1,086,363	2.71%	66,072
4 Withdrawn	-	-		-	-	-
5 Reappoint EY	39,266,710	97.73%		910,387	2.27%	33,766
6 Reappoint PKF Littlejohn LLP as Auditors	40,142,582	99.91%		37,614	0.09%	30,667
7 Authorise Board to Fix Remuneration of Auditors	40,105,519	99.81%		77,729	0.19%	27,615
8 Authorise Issue of Equity	38,484,392	95.78%		1,697,234	4.22%	29,237
Special resolutions
9 Authorise Issue of Equity without Pre-emptive Rights	38,467,804	95.74%		1,710,946	4.26%	32,113
10 Authorise Market Purchase of Ordinary Shares	39,597,340	99.87%		51,284	0.13%	562,239
11 Adoption of new articles	40,059,859	99.74%		104,681	0.26%	46,323

For further information, please contact: 

Renalytix plc		www.renalytix.com
James McCullough, CEO		Via Walbrook PR
Stifel (Nominated Adviser, Joint Broker)		Tel: [phone]
Alex Price / Nicholas Moore / Nick Harland / Samira Essebiyea
Investec Bank plc (Joint Broker)		Tel: [phone]
Gary Clarence / Shalin Bhamra
Walbrook PR Limited		Tel: [phone] or [e-mail]
Paul McManus / Alice Woodings / Charlotte Edgar	Mob: [phone]

About Renalytix

Renalytix (NASDAQ: RNLX) (LSE: RENX) is an in-vitro diagnostics and laboratory services company that is the global founder and leader in the new field of bioprognosis™ for kidney health. The leadership team, with a combined 200+ years of healthcare and in-vitro diagnostic experience, has designed its KidneyIntelX laboratory developed test to enable risk assessment for rapid progressive decline in kidney function in adult patients with T2D and early CKD (stages 1-3). We believe that by understanding how disease will progress, patients and providers can take action early to improve outcomes and reduce overall health system costs. For more information, visit www.renalytix.com.

 

END